Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9851–9900 of 18658
On June 12, 2023, Michael F. Carotenuto, Executive Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of Cambridge Bancorp (the “Company”) and Chief Financial Officer of Cambridge Trust (the “Bank”) notified the Company of his decision to pursue other career opportunities and resign from his roles at the Company and the Bank.
Mr. Joseph P. Sapienza, the Bank’s Controller, is expected to be named Interim CFO as the Company performs a search for Mr. Carotenuto’s replacement.
On June 6, 2023, Daniel Rogers notified the board of directors of Newcourt Acquisition Corp (the “Company”) that he has resigned from his position as Chief Financial Officer the Company, effective June 7, 2023.
On June 12, 2023, Kiromic BioPharma, Inc. (the "Company") appointed Brian Hungerford as interim Chief Financial Officer of the Company.
Mr. Baobing He, the Chief Executive Officer and Director of the Company, to be appointed as the Chief Financial Officer of the Company
Ms. Maggie Torres resigned as Interim Chief Financial Officer and Interim Treasurer of the Company and moved to the role of Director of Accounting Projects.
has appointed Dennis C. Schemm (age 57) as the Company’s Chief Financial Officer and Treasurer, effective as of June 12, 2023
Mr. Adams is expected to continue to serve as CEO until his successor joins the Company, at which time Mr. Adams will resign from the Company’s Board of Directors and will transition to non-executive employment with the Company as a special advisor to assist the CEO successor with transition matters for six months.
Effective June 6, 2023, Mr. Gregory Downey was dismissed as the Company’s Chief Financial Officer.
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
On June 6, 2023, Michelle M. Harrison, Senior Vice President, Finance and Treasurer of the Company notified the Company of her decision to retire after more than 23 years of service with the Company.
In connection with Ms. Harrison's retirement, Peter A. Trpkovski, who is currently serving as Vice President, Finance and Investor Relations of the Company, will be promoted to the role of Senior Vice President, Finance and Treasurer, effective July 1, 2023.
appointed Paul H. Pickle to serve as the Company’s President and Chief Executive Officer effective as of a date, after June 8, 2023 and not later than June 30, 2023, to be mutually agreed between Mr. Pickle and the Chair of the Board (with Mr. Pickle’s first day of employment in such capacity, the “Transition Date”). On June 7, 2023, Mr. Pickle and the Chair of the Board agreed that the Transition Date will be June 30, 2023.
Mohan Maheswaran’s retirement as the Company’s President and Chief Executive Officer, and as a member of the Board, will be effective June 29, 2023.
In connection with the termination of his employment with the Company, effective May 15, 2023, Mr. Remondi will be provided with severance payments and benefits in accordance with the Severance Plan
On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023
who resigned from his position as Chief Financial Officer and Chief Accounting Officer (as previously disclosed in the Company’s Current Report on Form 8-K filed on March 24, 2023), effective as of June 1, 2023.
the Company announced that Harsha V. Agadi ceased to serve as Interim Chief Executive Officer of the Company, also effective as of June 6, 2023, but will remain on the Board and assume the role of Non-Executive Chairman effective as of June 8, 2023.
the Board of Directors of the Company (the “Board”) has appointed Dr. Ryan Ezell, the Company’s existing President, to serve as its Chief Executive Officer, effective as of June 6, 2023.
the board of directors of the Company (the “Board”) appointed Mr. Andrew Taylor, age 52, as Chief Financial Officer of the Company to succeed Mr. Kaswan, effective as of the Separation Effective Date.
Mr. Michael Kaswan, the Company’s Chief Financial Officer, mutually agreed to terms pursuant to which Mr. Kaswan will step down as the Company’s Chief Financial Officer and separate from employment effective as of June 6, 2023
following the retirement of Murray Kessler from those same positions on the same day
announced the appointment of Mr. Patrick Lockwood-Taylor, 54, as President, CEO and director, effective June 30, 2023
Ms. Mason’s employment with the Company ended on May 4, 2023, which the Compensation Committee of the Company’s Board of Directors determined was a termination without cause under her employment agreement with the Company.
Tom O'Neil ceased serving as Chief Financial Officer of the Company
John Kollins ceased serving as President and Chief Executive Officer of the Company
Effective May 19, 2023, our Board of Directors, approved the appointment of Jeffrey M. Canouse as Chief Executive Officer and Director.
Matt Aune would be leaving his role as Chief Financial Officer, effective as of June 2, 2023
Additionally, Mr. Brounstein, the Company’s Chief Financial Officer, announced plans to retire and his resignation will be effective October 31, 2023.
On June 5, 2023, Michael Wittmeyer notified A-Mark Precious Metals, Inc. ("A-Mark" or the "Company") of his intention to resign as Chief Executive Officer of JM Bullion, Inc. ("JMB"), a wholly owned subsidiary of A-Mark, effective July 1, 2023
the Board appointed Brian Shea, age 35, the Company's General Counsel and Secretary, as the Company's Interim Chief Executive Officer and President.
On May 31, 2023 during a meeting of the Board of Directors, Fred Cooper, a major shareholder of KwikClick, Inc., was nominated, unanimously approved, and appointed to serve as the Chairman of the Board of Directors of the Company.
On June 6, 2023, the Board of Directors of Phoenix Motor Inc., a Delaware corporation (the “Company”), appointed its Chairman, Xiaofeng Peng to replace Dr. Lance Zhou as the Company’s Chief Executive Officer effective immediately.
On June 6, 2023, the Board of Directors of Phoenix Motor Inc., a Delaware corporation (the “Company”), appointed its Chairman, Xiaofeng Peng to replace Dr. Lance Zhou as the Company’s Chief Executive Officer effective immediately.
Ms. Drayton stepped down as Chief Financial Officer and Treasurer of the Company on May 12, 2023
On June 5, 2023, the Board of Directors (the “ Board ”) of the Company terminated Matthew Furlong as President and Chief Executive Officer of the Company, effective immediately
On June 1, 2023, and effective as of the date thereof, Delcath Systems, Inc. (the “Company”) appointed Sandra Pennell as Senior Vice President of Finance and principal financial and accounting officer of the Company.
On June 2, 2023, Amit Joshi, Chief Financial Officer of Apollo Debt Solutions BDC (the “Company”), notified the Company of his intention to resign.
Mr. Brito was appointed as President, Chief Executive Officer and Secretary of the Company.
Douglas V. Martin (“Martin”) resigned as the Company’s Interim CEO.
Surendra Ajjarapu and Francis Knuettel II were appointed as the Company’s Chief Executive Officer and Chairman and Chief Financial Officer, respectively
Surendra Ajjarapu and Francis Knuettel II were appointed as the Company’s Chief Executive Officer and Chairman and Chief Financial Officer, respectively
On June 1, 2023, the Board of Directors (the “Board”) of the Company appointed Mr. Keith Siegner to serve as Executive Vice President and Chief Financial Officer of the Company, effective June 30, 2023.
On June 1, 2023, Ms. Donna Dellomo, the Chief Financial Officer, principal accounting officer, Secretary and Treasurer of The Lovesac Company (the “Company”) informed the Company that she will resign from her role effective June 30, 2023.
On June 2, 2022, the Board appointed Miles Jennings, age 45, a current Board member, to serve as the Chief Executive Officer.
Effective June 1, 2023, Mr. Long Ding Jung resigned as a Chief Executive Officer of Leet Technology Inc. (the “Company”).
Effective June 7, 2023, the board of directors (the “Board”) appointed Mr. Song Dai who has been a director of the Company since October 23, 2020, as the Company’s interim Chief Executive Officer.
Thomas Ernst, the Company's Chief Financial Officer and Treasurer, assumed the responsibilities of chief accounting officer effective as of June 5, 2023
Sameer Ralhan, Senior Vice President of The Chemours Company (the “Company”), notified the Company of his intention to resign, effective June 19, 2023.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.